Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02562820 · ClinicalTrials.gov registry record · Phase 1
An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome
A Phase 1 study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02562820: Clinical Trial Phase 1 study, sponsored by The Cleveland Clinic.
NCT02562820 is a Phase 1 study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02562820, a Phase 1 study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Rett Syndrome (RTT) is a complex disorder resulting from mutations in a gene encoding the MeCP2 protein. Currently, there are no methods to fix the abnormal gene, however, animal studies suggest that the symptoms of RTT can be treated. Ketamine is a sedative or anesthetic, depending on the dose. The drug is approved by the US Food and Drug Administration (FDA) and is commonly used in children and adults. Animal studies and case reports in humans suggest that ketamine may reduce the symptoms of Rett syndrome. The purpose of this study is to determine the safety and efficacy of ketamine for treating breathing and behavioral symptoms of RTT.
Primary Outcome
Occurrence of agitation, irritability, or worsening of pre-existing symptoms.
Interventions
- PROCEDURE Intravenous infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-07 |
| Phase | Phase 1 |
Why NCT02562820 stopped before completion
NCT02562820 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Intravenous infusion is the first listed.
NCT02562820 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02562820 about?
NCT02562820 is a clinical study titled "An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome". Rett Syndrome (RTT) is a complex disorder resulting from mutations in a gene encoding the MeCP2 protein. Currently, there are no methods to fix the abnormal gene, however, animal studies suggest that the symptoms of RTT can be treated. Ketamine is a sedative or anesthetic, depending on the dose. Th...
What is the current status of trial NCT02562820?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-11. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02562820?
The interventions under investigation include: Intravenous infusion (PROCEDURE).
Who is sponsoring clinical trial NCT02562820?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02562820's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia